Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Hristos Polymeropoulos Sells 77,225 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos sold 77,225 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $15.56, for a total value of $1,201,621.00. Following the completion of the transaction, the chief executive officer now owns 1,276,343 shares of the company’s stock, valued at approximately $19,859,897.08. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

  • On Tuesday, May 21st, Mihael Hristos Polymeropoulos sold 72,872 shares of Vanda Pharmaceuticals stock. The shares were sold at an average price of $15.34, for a total value of $1,117,856.48.
  • On Monday, March 4th, Mihael Hristos Polymeropoulos sold 38,166 shares of Vanda Pharmaceuticals stock. The shares were sold at an average price of $19.41, for a total value of $740,802.06.
  • On Friday, March 1st, Mihael Hristos Polymeropoulos sold 6,500 shares of Vanda Pharmaceuticals stock. The shares were sold at an average price of $20.22, for a total value of $131,430.00.

Shares of NASDAQ VNDA traded up $1.48 during trading on Tuesday, reaching $16.39. 746,467 shares of the stock traded hands, compared to its average volume of 834,370. Vanda Pharmaceuticals Inc. has a 52-week low of $13.66 and a 52-week high of $33.44. The stock has a market capitalization of $789.69 million, a PE ratio of 33.77 and a beta of 0.44.



Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.08). Vanda Pharmaceuticals had a net margin of 10.92% and a return on equity of 8.07%. The firm had revenue of $47.71 million for the quarter, compared to analysts’ expectations of $51.74 million. During the same period in the prior year, the company earned $0.14 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. As a group, research analysts forecast that Vanda Pharmaceuticals Inc. will post 0.06 earnings per share for the current fiscal year.

A number of research analysts have issued reports on the company. BidaskClub downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. ValuEngine downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 4th. Cantor Fitzgerald downgraded Vanda Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $38.00 to $30.00 in a research note on Wednesday, February 6th. Stifel Nicolaus restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 6th. Finally, Oppenheimer dropped their price target on Vanda Pharmaceuticals from $29.00 to $21.00 in a research report on Thursday, February 14th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $33.63.

Several hedge funds and other institutional investors have recently modified their holdings of VNDA. SEI Investments Co lifted its holdings in Vanda Pharmaceuticals by 4.0% during the 1st quarter. SEI Investments Co now owns 171,892 shares of the biopharmaceutical company’s stock worth $3,158,000 after purchasing an additional 6,565 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Vanda Pharmaceuticals by 25.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 830,735 shares of the biopharmaceutical company’s stock worth $15,286,000 after purchasing an additional 169,200 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Vanda Pharmaceuticals by 86.6% during the 1st quarter. Voya Investment Management LLC now owns 40,406 shares of the biopharmaceutical company’s stock worth $743,000 after purchasing an additional 18,752 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Vanda Pharmaceuticals by 7.1% during the 1st quarter. Geode Capital Management LLC now owns 639,094 shares of the biopharmaceutical company’s stock worth $11,759,000 after purchasing an additional 42,468 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Vanda Pharmaceuticals by 19.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 436,312 shares of the biopharmaceutical company’s stock worth $8,029,000 after purchasing an additional 72,121 shares in the last quarter. 98.58% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Hristos Polymeropoulos Sells 77,225 Shares” was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://dakotafinancialnews.com/2019/05/21/vanda-pharmaceuticals-inc-vnda-ceo-mihael-hristos-polymeropoulos-sells-77225-shares.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Read More: What are the benefits of buying treasury bonds?

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.